^
    4d
    Molecular Profiling and Real-World Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer. (PubMed, Clin Cancer Res)
    BRAF-mut PTC is associated with a pro-inflammatory TME milieu compared to BRAF-wt PTC. However, in this limited data set, treatment choice was not associated with differences in OS in BRAF-mut PTC.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • ETV6 (ETS Variant Transcription Factor 6) • IFNG (Interferon, gamma)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • HRAS mutation
    14d
    Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer (clinicaltrials.gov)
    P1, N=31, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • MAP2K2 (Mitogen-activated protein kinase kinase 2)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation
    |
    everolimus • Avmapki (avutometinib) • Fakzynja (defactinib)
    27d
    Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Changhai Hospital | Trial completion date: Mar 2025 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Jun 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • HRAS mutation • KRAS G12 • NRAS G12
    |
    cyclophosphamide • fludarabine IV
    27d
    Schimmelpenning-Feuerstein-Mims syndrome: a systematic review of clinical cases to identify genotype-phenotype associations. (PubMed, Front Med (Lausanne))
    The data obtained indicates the necessity of genetic testing for all patients suspected of SFMS to determine the individual risk of comorbidities and to form a personalized plan for dynamic follow-up. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085872, identifier CRD420251085872.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • RAS mutation • HRAS mutation
    1m
    No prognostic or molecular disparity between synchronous and metachronous metastases in differentiated thyroid cancer: insight from middle eastern cohort. (PubMed, Int J Surg)
    In this Middle Eastern cohort, no consistent molecular or clinical disparities across most parameters. These findings suggest the timing of metastasis may not independently influence prognosis and highlight the relevance of individualized, biology-driven management strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase)
    |
    PD-L1 expression • TP53 mutation • BRAF V600E • PD-L1 overexpression • BRAF V600 • HRAS mutation
    1m
    Clinical and Biochemical Characteristics of Patients with Somatic HRAS-mutant Pheochromocytoma and Paraganglioma. (PubMed, Eur J Endocrinol)
    Patients with HRAS-mutant PPGL have higher plasma metanephrine levels and a higher risk of IHI and ICU transfer, which therefore requires personalized perioperative managements.
    Journal
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    HRAS mutation
    2ms
    Induction chemotherapy followed by radiotherapy in primary small cell neuroendocrine carcinoma of the parotid gland: a case report and literature review. (PubMed, Chin Clin Oncol)
    These findings yield valuable insights into the biological and clinical behaviors of this rare parotid gland neoplasm. Furthermore, this work enhances the understanding of the epidemiological characteristics and optimal management strategies for parotid gland SCNC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    PD-L1 expression • TP53 mutation • HRAS mutation
    2ms
    Clinicopathologic and molecular characterization of a series of sporadic trichoblastic neoplasms. (PubMed, Virchows Arch)
    Additionally, a FOXK1::GRHL1 fusion was found in the case of trichogerminoma. Clinical follow-up (15/16 patients; 94%; median: 65 months; range 2.5-106.5 months) showed no evidence of residual or metastatic disease.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TMB-H • HRAS mutation
    2ms
    Structural and allosteric effects of the membrane-bound PI3Kα H1047R mutation and opportunities for drug discovery. (PubMed, Commun Chem)
    WT and mutant proteins adopt distinct conformational ensembles on the membrane, enabling structure-based prediction of allosteric pockets at the protein-membrane interface. These findings offer a mechanistic basis for the H1047R enhanced membrane-binding ability and insights for new therapeutic strategies targeting the protein-membrane interface.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    HRAS mutation
    2ms
    Orbital Rhabdomyosarcoma in a Pediatric Patient With Costello Syndrome. (PubMed, Ophthalmic Plast Reconstr Surg)
    Treatment with chemotherapy consisted of vincristine, dactinomycin, and cyclophosphamide, and received 8 cycles of photon beam radiation. Radiological surveillance up to 12 months showed no signs of recurrence or metastatic lesions. Patients with CS are at a high risk of developing rhabdomyosarcoma and clinicians should be vigilant in the context of any clinical orbital signs of disease.
    Journal
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    HRAS mutation
    |
    cyclophosphamide • vincristine • dactinomycin
    3ms
    Myoepithelial and Epithelial-myoepithelial Clinically Advanced and Metastatic Carcinomas of Salivary Gland: A Comparative Comprehensive Genomic Profiling Study. (PubMed, Hum Pathol)
    Although not significantly different, CDKN2A and CDKN2B alterations were more frequent in MECA, while PIK3CA alterations were more frequent in EMC. Overall, EMC and MECA had both overlapping and unique molecular alterations that have potential for targeted therapies.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MDM2 (E3 ubiquitin protein ligase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    PIK3CA mutation • HRAS mutation
    3ms
    Malignant struma ovarii: clinicopathological and molecular features in a series of nine cases. (PubMed, Virchows Arch)
    In conclusions, MSO shares histomolecular overlap with primary thyroid carcinoma, validating WHO 2022 thyroid tumor classification for risk stratification in struma ovarii. Conservative surgical management achieves excellent outcomes in low-grade cases.
    Journal • BRCA Biomarker
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • RET (Ret Proto-Oncogene) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • KMT2C (Lysine Methyltransferase 2C) • RAS (Rat Sarcoma Virus) • NCAM1 (Neural cell adhesion molecule 1) • NKX2-1 (NK2 Homeobox 1) • KRT19 (Keratin 19) • PAX8 (Paired box 8) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
    |
    BRAF mutation • RET fusion • PTEN mutation • RET mutation • HRAS mutation • NRAS Q61 • BRAF G469A